Synergy of short antimicrobial peptides with β-lactam antibiotics against MRSA resides in the degradation of peptidoglycan barrier

0522930 - ÚOCHB 2020 IE eng C - Konferenční příspěvek (zahraniční konf.)
Nešuta, Ondřej - Kyznar, Jakub - Volejníková, Andrea - Čeřovský, Václav
Synergy of short antimicrobial peptides with β-lactam antibiotics against MRSA resides in the degradation of peptidoglycan barrier.
Proceedings of the 35th European Peptide Symposium. Dublin: European Peptide Society, 2018 - (Timmons, P.; Hewage, C.; Lebl, M.), s. 217-219
[European Peptide Symposium /35./. Dublin (IE), 26.08.2018-31.08.2018]
Grant CEP: GA MZd(CZ) NV16-27726A
Institucionální podpora: RVO:61388963
Klíčová slova: antimicrobial peptides * MRSA * peptidoglycan * beta-lactams * synergy
Obor OECD: Microbiology

The emerging resistance of bacteria to currently used antibiotics is becoming a significant global problem that requires searching for alternative antimicrobial agents. One of the most frequently reported pathogens, methicillin-resistant Staphylococcus aureus (MRSA), which causes infections of wounds, bones, implants, bloodstream, skin, pneumonia, etc., is a typical example of Gram-positive bacterium that possess resistance to several antibiotics, including β-lactams. Therapeutic options are becoming limited, and vancomycin remains as the last resort for treating MRSA, but not for long. Antimicrobial peptides (AMPs) have long been considered as a possible new class of anti-infective agents that could be used as a supplement to, or substitute for, conventional antibiotics in the fight against multi-drug resistant bacteria. Their potential advantage resides in a unique mechanism of action that involves interacting with the negatively charged phospholipid bilayer of bacterial cell membrane causing its disruption via pore formation or detergent-like disintegration, thereby leading to cell death. However, in Gram-positive bacteria, AMPs have to first pass through the cell wall that consists prevalently of a peptidoglycan layer, before reaching its target - the cytoplasmic membrane. Several reports have shown a significant synergistic antimicrobial effect when AMPs were applied in combination with common antibiotics. In this work, we examined a combination of short linear AMPs, previously invented in our laboratory, with β-lactam antibiotics against a reference strain of MRSA (ATCC 43300) in order to shed light on the mechanism of the synergy between AMPs and β-lactam antibiotics.

Trvalý link: http://hdl.handle.net/11104/0307377